Products and Resources Catalog

    This webinar focuses on increasing knowledge among providers in the assessment and treatment of wounds as related to intravenous drug and xylazine use.     LEARNING OBJECTIVES: Explain opioid use disorder as a chronic illness. Increase level of comfort in the treatment and assessment of wound care as it relates to intravenous drug and Xylazine use. Share best practices for incorporating harm reduction philosophies and principles in the treatment of opioid use disorder (OUD).     TRAINERS:   Nicole Gastala, MD   Dr. Gastala is board certified in Family Medicine and Addiction Medicine. She graduated from Loyola Stritch School of Medicine and completed her Family Medicine residency at the University of Iowa. In her clinical role, she has developed and expanded MAR by mentoring new prescribers, precepting residents, and training clinicians within the Chicago and Illinois communities.  She has also focused on the development of a walk-in integrated behavioral health, addiction, and primary care program within her FQHC system. In January 2021, Dr Gastala joined the team at the Substance Use Prevention and Recovery Division of IDHS as the medical director.     Michael Huyck, NP   Michael Huyck is a Family Nurse Practitioner at the UIH Mile Square Health Center and adjunct clinical assistant professor with the University of Illinois College of Nursing. His clinical role at Mile Square is focused on integrative substance use disorder treatment and primary care. His clinical interests involve decreasing barriers to addiction care, piloting evidenced based interventions to address problems specific to populations with SUD, and training future nurses to care for those experiencing addiction. He provides a full range of SUD treatment including buprenorphine and methadone within his practice. His current projects include wound care and ultrasound guided phlebotomy for people who inject drugs.     The Great Lakes A/MH/PTTC is offering this training for individuals working in HHS Region 5: IL, IN, MI, MN, OH, WI. This training is being provided in response to a need identified by Region 5 stakeholders.

    DESCRIPTION: As the illicit opioid supply includes more and more fentanyl, there have been increasing concerns about increasing rates of buprenorphine initiation precipitating opioid withdrawal. This session will describe why we believe this is happening, how common it is, and buprenorphine initiation strategies to support patients in avoiding precipitated withdrawal.     LEARNING OBJECTIVES: Describe the challenges of buprenorphine initiation in the fentanyl era. Name three potential approaches to buprenorphine initiation. Counsel on reducing fentanyl-related harms.     TRAINER: Elizabeth Salisbury-Afshar, MD, MPH is an Associate Professor in the Departments of Family Medicine and Community Health and Population Health Sciences at the University of Wisconsin School of Medicine and Public Health in Madison, Wisconsin. She is the Program Director of the Preventive Medicine Residency and core Faculty for the Addiction Medicine Fellowship. Dr. Salisbury-Afshar is board certified in family medicine, preventive medicine/public health and addiction medicine and her expertise lies at the intersection of these fields. Her work has focused on expanding access to evidence-based substance use disorder treatment and harm reduction services. Past public health roles include serving as Medical Director of Behavioral Health Systems Baltimore, Medical Director at Heartland Alliance Health (a healthcare for the homeless provider in Chicago), and Medical Director of Behavioral Health at the Chicago Department of Public Health. Dr. Salisbury-Afshar received her Medical Degree from Rush University Medical College and her Master’s in Public Health from John Hopkins Bloomberg School of Public Health.     The Great Lakes A/MH/PTTC is offering this training for individuals working in HHS Region 5: IL, IN, MI, MN, OH, WI. This training is being provided in response to a need identified by Region 5 stakeholders.

Throughout the month of September 2022, the Idaho Department of Health & Welfare in partnership with Recovery Idaho, Idaho Harm Reduction Project, and the Northwest ATTC hosted a series of online webinars titled “Recovery is Health, Health is Recovery." During the series, presenters discussed a range of topics relating to transmissible disease, treatment and precautionary measures, as well as harm reduction practices. Part 1: September 7, 2022 Presenters: Evan Burke (Idaho Harm Reduction Project) and Norma Jaeger (Recovery Idaho) In this session, Evan Burke offered a brief overview of the data on opioid overdose in Idaho and the response to it by government and community-based organizations. Burke also covered how to recognize and respond to an overdose and provide guidance about harm reduction informed practices. Norma Jaeger talked about the RxAware Program, which will address risks associated with opioids and pain management. Read more about this session and its presenters.  Watch the recording | Download slides | RxAware toolkit | RxAware flyer

The Naloxone is an Act of Love website was developed with support by the New England Addiction Technology Transfer Center (ATTC) in partnership with the Center of Biomedical Research Excellence (COBRE) on Opioids and Overdose. The website hosts a suite of resources designed to reduce stigma surrounding the use of naloxone and those who experience an opioid overdose along with encouraging viewers to get trained in and carry Naloxone. Specific resources include narrative videos, posters, and coasters. 

In partnership with Brown University SciToons and the Department of Emergency Medicine, the New England ATTC created the product "Opioid Overdose Rescue: 5 Ways to Save the Life." This educational video teaches the viewer how to recognize an overdose and how to effectively intervene. Watch the video to learn more. 

This webinar will review the pharmacological characteristics of stimulant medications and also medications that provide a stimulant effect and review which medications are most effective in enhancing natural recovery and improving fatigue and cognitive functioning in TBI survivors. A discussion regarding the similarity of ADHD symptoms to TBI symptoms will be presented. Frontal lobe and temporal lobe syndromes will be described, and specific medications will be reviewed that are likely to have a positive impact on the TBI survivor. Case studies will also be presented exemplifying the complexity of brain injury, cognitive impairment and effective use of medications.   Learning Objectives: Review the definitions, similarities and differences between Stimulant medications Describe the symptoms of TBI following or during rehabilitation Differentiate levels of TBI cognitive severity Understand the Psychopharmacology of Stimulant Medications Describe atypical stimulants, non-stimulants and antidepressants Understand the complexity of choosing a stimulant medication in a patient with TBI   Presenter Information Dr. Sparadeo began his career as the Director of the Mayor’s Task Force on Substance Abuse in the City of Providence, R.I. and he was also the Director of Substance Abuse Services for the Providence Mental Health Center at that same time. After creating a system of clinical services for the City of Providence he was appointed as CEO of Talbot House. Talbot House was the largest residential substance abuse treatment facility in New England. Dr. Sparadeo then completed his doctoral studies with a residency at the Boston V.A. Medical Center followed by a 2-year fellowship at Brown University and Rhode Island Hospital (RIH). The focus of his clinical training was neuropsychology and chronic pain. He completed his fellowship and was appointed to the Brown University School of Medicine faculty and the Rhode Island Hospital medical staff in the position of Director of Rehabilitation Psychology. Dr. Sparadeo trained numerous interns and fellows at Brown University. As Director of Rehabilitation Psychology, Dr. Sparadeo created the first comprehensive outpatient rehabilitation program for survivors of traumatic brain injury. After 8 years in his position at RIH Dr. Sparadeo was appointed National Director of Substance Abuse and TBI rehabilitation services at New Medico Health Systems in Boston, Massachusetts. He created inpatient substance abuse treatment programs in 8 rehabilitation facilities throughout the U.S. He returned to RIH and Brown University to become the director of the Concussion Care Center in the Emergency Department at RIH. He was also the chief clinical consultant to the Trauma Center and Stepdown Unit, and he was the co-director of the Interdisciplinary Spine Center in the Neurosurgery Department at RIH for 5 years before opening a private practice specializing in the neuropsychological assessment, pain assessment and pain management. He developed a specialized substance abuse treatment program for people with both TBI and substance abuse. Eventually, he developed a specialized treatment program for people with chronic pain and opiate addiction. Over the many years of his career Dr. Sparadeo has been a consultant to many agencies and healthcare programs throughout the U.S. He has also served on numerous boards of directors. He was the founder and president of the Brain Injury Association of Rhode Island. He was also the Chairman of the Governor’s Permanent Advisory Commission on TBI. He was also a member of the national committee on substance abuse and disability at SAMHSA in Washington, D.C. Most recently, Dr. Sparadeo has been a consultant and chief trainer on a federally funded grant at the Massachusetts Rehabilitation Commission. Dr. Sparadeo’s career has also included the publication of many scientific papers and book chapters, and he has been on the faculty of Salve Regina University graduate program in Rehabilitation Counseling where he teaches the Neuroscience of Substance Abuse and Mental Illness, Psychopharmacology for Counselors and the Neuroscience of Opioid Abuse.   Traumatic Injury & SUD: Implications of Stimulants on Traumatic Brain Injury  

These Telehealth MOUD Video Demonstrations show distinct clinical interactions common across the medications for opioid use disorder (MOUD) modality. Except for the first two videos listed (Buprenorphine Induction and Re-induction to Buprenorphine), which show the same mock patient at two stages along his treatment trajectory, the videos in this collection are independent depictions showcasing different settings, patient situations, and provider types. The common thread for these videos is that each patient portrayed has an opioid use disorder and is considering or engaged in medication treatment. This set of videos may be useful for individuals entering the MOUD workforce or for MOUD patients and family members curious about what happens at various points in treatment.  Produced by the Northwest ATTC (SAMHSA grant no. TI080201), in co-sponsorship with Southeast ATTC (SAMHSA grant no. TI080215) and the ATTC Network Coordinating Office (SAMHSA grant no. TI080205). We thank the clinicians involved for their conceptual contributions to the development of these characters and the clinical scenario.

  Understanding addiction is essential to successfully addressing it. In this overview of substance use we discuss the spectrum of use, neurobiological responses to substances, signs and symptoms that explain the disorders, and the common definition of SUDs.  

Provides an overview of resources and initiatives to address opioid misuse in Michigan. Information effective May 2019. 

The April 2019 Dialogue features: Addiction: Alcohol and CAncer | Mental Health: Mental Health Problems Linked to How American Youth Spend Their Time | Prevention: Take Back Drug events for prevention | ORN: SUD Treatment Gap. Additional sections include upcoming training and webinar events, behavioral health observances, new resources, Region 3 news, and Region 3 Spotlight: National American Indian and Alaska Native Mental Health Technology Transfer Center. The Dialogue is designed to inform behavioral and mental health professionals of news and upcoming events in the Central East states. This electronic newsletter is disseminated on the first Tuesday of each month. We encourage you to provide any feedback or submit articles and topics for discussion in future issues of the newsletter. If you would like to be added to our mailing list to receive the Dialogue, news, and training announcements, sign up here.

Overview: Methamphetamine is the number 1 drug threat ranked by the Dallas, El Paso, and Houston DEA Field Divisions. Cocaine is ranked the number 2 and number 3 threat by the DEA Field Divisions. Pharmaceuticals, benzodiazepines, hydrocodone, and muscle relaxants remain problematic. Compared to other NDEWS sites, the number of fentanyl items seized and identified is increasing, but the number of cases involving heroin and fentanyl in combination is low, while the number of cases involving fentanyl and other opiates is high. The recent increase in the number of tramadol cases involved with other opiates is also a concern. Heroin in Texas is either black tar heroin or powdered brown heroin (diluted with diphenhydramine or other filler), with some white Mexican/South American heroin seen. Of the top 25 items seized and identified in Texas laboratories reporting to the National Forensic Laboratory Information System (NFLIS), heroin ranks #4, at 5.2% of all items identified, and fentanyl ranks #21 (0.21% of all items identified). Cannabis indicators remain steady, with problems most often seen in the trafficking of decriminalized cannabis products from Colorado through Texas. Synthetic cannabinoid and cathinone poison calls have decreased but recent research by the author looking at treatment admissions and poison center call data has found statistically significant trends over time. The user population has changed from younger males hoping to use a cannabinoid that would not show positive in drug tests to an older population who are more likely to be experiencing homelessness and co-morbid psychological problems.

This webinar, held in November 2018, was sponsored by the Northwest ATTC and the Western States Node of the NIDA Clinical Trials Network. It reviews the biological basis of medications for opioid use disorder, reviews recent data on the effects of buprenorphine on patient outcomes, and introduces tools for integrating buprenorphine treatment into your current treatment setting. Presenter: P. Todd Korthuis, MD, MPH, Oregon Health & Science University, NIDA Clinical Trials Network Western States Node Download slides | Watch recording

J. Paul Seale, MD, Certified by the American Boards of Family Medicine and Addiction Medicine, discusses America’s ongoing opioid epidemic. By the end of this one hour program, participants should be able to: 1) identify several key developments in the origin of the opioid epidemic, 2) describe strategic initiatives that are in progress to address the epidemic, and 3) identify specific steps forward that could help address the epidemic.

This presentation discusses strategies to identify South Africa HIV ATTC training and technical assistance offerings that meet stakeholder needs, particularly with mental health and substance use topics. We particularly focus on the Screening, Brief Intervention, and Referral to Treatment (SBIRT) training model.

This webinar provides an overview of the Substance Use Disorders Initiative, a program developed at Massachusetts General Hospital to improve the quality, clinical outcomes, and value of addiction treatment by implementing a chronic disease model of care across the system. The Initiative includes inpatient and outpatient clinical services, SUD specific treatment services in the ED, integration of addiction services into primary care, and more.

Presentation by Dr. Michael McNett on alternatives to opioids for pain management.

Reference reading list of sources for HIV clinicians concerning medical marijuana.

This presentation provides an overview of drug and alcohol use in South Africa, with a particular focus on people living with HIV. Additionally, the South Africa HIV ATTC's mission, objectives, and training targets are contextualised within this drug and alcohol addiction context.

This two-part webinar will review SUD diagnosis criteria, the impact of SUD on the brain and compulsivity factor, as well as specific signs and symptoms for alcohol and opioid use disorders (AUD, OUD). The content will further explain how medicated assisted treatment (MAT) works, why it’s the most effective treatment for OUD and AUD, and will include points for providers to effectively inform clients on how MAT increases a person’s opportunity for access and sustain recovery.

This presentation was created and delivered by Mr. Kgalabi Ngako, a National Department of Health representative for the Mental Health and Substance Abuse Directorate. It discusses adopting Screening, Brief Intervention and Referral to Treatment (SBIRT) curriculum as a strategy to combat substance use disorders.

Mid-America ATTC has developed a 2018 version of the Hepatitis Awareness Month (May) Info Sheet and Bulletin Insert. Side one has been updated to focus on the dual epidemics of the opioid crisis and hepatitis C virus (HCV). Although the document was initially designed for the faith community, it is appropriate as an educational flyer for much broader audiences. This product can be easily downloaded and used by churches, temples and mosques for their Sunday/Sabbath-day bulletins, newsletter

Joseph O. Merrill, MD, MPH, UW Associate Professor of Medicine April 25, 2018 Dr. Merrill is a UW associate professor of medicine and a certified expert in addiction medicine. He has clinical and research expertise in primary care, addiction medicine, pain medicine, and HIV medicine. As a member of the UW School of Medicine Colleges Faculty, he is active in medical student education. He teaches students, residents, and practicing physicians in a wide variety of settings. Download slides | Watch recording

This double-sided handout in Spanish can be given to and discussed with patients during the brief intervention. Side one contains information on prescription opioids and heroin, including mixing opioids with other substances, risks of opioid use, how to safeguard prescription opioids, steps to take if using opioids, and tips for quitting. Side two describes the effects of opioid misuse on the body.

This double-sided handout can be given to and discussed with patients during the brief intervention. Side one contains information on prescription opioids and heroin, including mixing opioids with other substances, risks of opioid use, how to safeguard prescription opioids, steps to take if using opioids, and tips for quitting. Side two describes the effects of opioid misuse on the body.